What the KLOW peptide research context tells us about doses — and what it cannot

In plain English

KLOW peptide does not have a validated human dose. There is no clinical trial that tested the four-peptide combination and established a dose, a schedule, or a safety threshold. The information below covers the composition of the research vial (what goes in it and how much of each peptide), the doses that were used in individual animal studies for each component, and the reason a single 'optimal dose' for the blend is not currently a meaningful concept.

The short reason: the four peptides in KLOW clear the body at very different rates. A dose that puts BPC-157 at a useful level in the bloodstream will not keep the small tripeptides KPV and GHK-Cu there at the same time. They simply disappear faster. That timing mismatch is built into the biology and cannot be fixed by adjusting the amounts in the vial. No human dosing recommendation appears on this site. The research context is documented here so readers can understand the existing literature accurately.

KLOW peptide dosage — the canonical vial composition

The canonical research vial composition listed across independent compounders is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu constitutes approximately 62.5% of the vial by mass, making it the mass-dominant component. The vial is supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic water for laboratory handling.

The 80 mg total and 50/10/10/10 ratio represent a research compounding convention, not a clinically validated formulation. No pharmacopoeial standard, FDA-reviewed dose, or approved labeling exists for KLOW peptide. The four components are independent molecules in solution; their doses in the vial do not interact to produce a combined pharmacological effect that has been characterized in any model.

KLOW dosage — what the component studies measured

Animal-model doses for the four constituents vary widely by species, route, tissue target, and research group. These are the study-reported doses from the cited literature — not recommendations for any application outside the original experimental context.

TB-500 / thymosin beta-4: Topical or intraperitoneal administration in a rat wound model; as little as 10 picograms active in migration assays ^[1]. Most foundational wound data were with full-length native thymosin beta-4, not the TB-500 heptapeptide fragment.

BPC-157: 10 micrograms, 10 nanograms, or 10 picograms per rat in Achilles tendon studies, administered intraperitoneally once daily ^[2]. 250 mcg/kg intraperitoneal in muscle crush-injury studies ^[8][9]. A human IV safety pilot used 10 mg on day 1 and 20 mg on day 2 in two adults ^[6] — a two-person, open-label, non-efficacy study.

KPV: 10 nanomolar in vitro; 100 micromolar in mouse drinking water (oral, colitis models) ^[3]. PepT1 Km approximately 160 micromolar for transporter affinity ^[3].

GHK-Cu: Low-nanomolar concentrations (1-10 nM) for transcriptomic and cell-culture findings ^[5]; topical formulation in clinical skin studies ^[4]. The liposomal delivery study used 0.5 mg/cm³ GHK-Cu in 25 mg/cm³ lipid liposomes ^[14].

These doses are not additive and cannot be extrapolated into a recommended KLOW blend dose. Species, route, tissue, and experimental duration all differ across studies.

KLOW peptide dosage and frequency — the pharmacokinetic mismatch

The pharmacokinetic mismatch inherent in the KLOW blend is a structural concern, not a peripheral note. BPC-157 has a short elimination half-life in formal rat pharmacokinetic characterization; KPV and GHK-Cu are linear tripeptides that clear even faster; and the TB-500 heptapeptide fragment behaves differently from the full-length thymosin beta-4 native protein on which most efficacy data rest.

A single co-formulated dose at a fixed 50/10/10/10 mg ratio therefore cannot maintain all four components at matched plasma exposures simultaneously. The large component (GHK-Cu at 50 mg) and the small components (10 mg each of BPC-157, TB-500, KPV) are present at very different molar amounts, and their clearance rates diverge further. Combination-dose modeling for this mixture does not exist in the peer-reviewed literature.

This mismatch is one reason why 'KLOW peptide dosage and frequency' cannot be answered with a single number from the existing literature. The question awaits combination-study data.

Stability and handling notes

The lyophilized blend is typically stored refrigerated and reconstituted with bacteriostatic water for laboratory use. The copper(II) ion in GHK-Cu can participate in redox chemistry — a theoretical peptide-oxidation consideration when co-dissolved with the three other peptides in one vial at elevated temperature or over extended storage. This incompatibility question has not been formally characterized for this specific mixture. The routes studied in component literature include subcutaneous injection (primary research-handling route), topical (GHK-Cu cosmetic and wound literature), oral or targeted intestinal delivery (KPV and BPC-157 gut models), and intra-articular (BPC-157 joint models). None of these routes have been characterized for the four-peptide co-formulation.